We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
+6.02%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$71M
AUM Growth
+$4.2M
(+6.3%)
Cap. Flow
+$4.27M
Cap. Flow
% of AUM
6.01%
Top 10 Holdings %
Top 10 Hldgs %
87.26%
Holding
18
New
1
Increased
9
Reduced
3
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$5.71M |
| 2 |
Cardinal Health
CAH
|
+$4.56M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$4.22M |
| 4 |
Cencora
COR
|
+$4.18M |
| 5 |
AbbVie
ABBV
|
+$3.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Supernus Pharmaceuticals
SUPN
|
+$8.93M |
| 2 |
Accuray
ARAY
|
+$7.35M |
| 3 |
Aldeyra Therapeutics
ALDX
|
+$2.72M |
| 4 |
Evolus
EOLS
|
+$2.29M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$2.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ironwood Pharmaceuticals
IRWD
$693M
| $8.51M | 11.99% |
730,000
+45,000
| +7% | +$552K |
|
|
2
McKesson
MCK
$101B
| $8.45M | 11.91% |
34,000
+26,000
| +325% | +$5.71M |
|
3
Harmony Biosciences
HRMY
$2.2B
| $8.31M | 11.72% |
195,000
+10,000
| +5% | +$399K |
|
|
4
AbbVie
ABBV
$433B
| $6.5M | 9.16% |
48,000
+33,000
| +220% | +$3.9M |
|
|
5
Cardinal Health
CAH
$55.9B
| $6.44M | 9.07% |
125,000
+93,000
| +291% | +$4.56M |
|
|
6
Cencora
COR
$61.7B
| $6.38M | 8.99% |
48,000
+34,000
| +243% | +$4.18M |
|
|
7
Bristol-Myers Squibb
BMY
$130B
| $6.24M | 8.79% |
100,000
+72,000
| +257% | +$4.22M |
|
8
Utah Medical Products
UTMD
$225M
| $4M | 5.64% |
40,000
-2,000
| -5% | -$204K |
|
|
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $3.86M | 5.44% |
830,000
+560,000
| +207% | +$2.33M |
|
|
LCI
10
DELISTED
Lannett Company, Inc.
LCI
| $3.24M | 4.57% |
500,000
+56,250
| +13% | +$482K |
|
|
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
| $3.17M | 4.47% |
195,000
-25,000
| -11% | -$366K |
|
|
ICPT
12
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.98M | 4.2% |
+183,000
| New | +$3.08M |
|
|
13
Rigel Pharmaceuticals
RIGL
$735M
| $2.89M | 4.07% |
109,000
-67,500
| -38% | -$2.04M |
|
|
14
Aldeyra Therapeutics
ALDX
$95.3M
| – | – |
-310,000
| Closed | -$2.72M |
|
|
15
Accuray
ARAY
$33.7M
| – | – |
-1,860,000
| Closed | -$7.35M |
|
|
16
Evolus
EOLS
$401M
| – | – |
-300,000
| Closed | -$2.29M |
|
|
17
Supernus Pharmaceuticals
SUPN
$2.75B
| – | – |
-335,000
| Closed | -$8.93M |
|
18
UroGen Pharma
URGN
$2.23B
| – | – |
-75,000
| Closed | -$1.26M |
|
Similar funds
KP
TCM
SAAM
PAA
PC
BOCH
GIP
PC
HealthInvest Partners's Q4 2021 Portfolio in Review
As of Q4 2021, HealthInvest Partners held 18 positions worth $71M, up 6.3% from $66.8M the previous quarter. Its ten largest holdings account for 87% of the portfolio.
HealthInvest Partners deployed $4.27M of net new capital in Q4 2021, opening 1 new position and adding to 9 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 183,000 shares worth $2.98M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Rigel Pharmaceuticals, an estimated $2.04M trimmed.
- HealthInvest Partners's largest Q4 2021 buy was Intercept Pharmaceuticals, Inc.: 183,000 shares worth $2.98M.
- HealthInvest Partners added most to McKesson in Q4 2021, an estimated $5.71M increase.
- HealthInvest Partners's biggest Q4 2021 reduction was Rigel Pharmaceuticals, cutting an estimated $2.04M.
- HealthInvest Partners fully exited Supernus Pharmaceuticals in Q4 2021, selling an estimated $8.93M.
- HealthInvest Partners's ten largest holdings make up 87% of its $71M portfolio in Q4 2021.
- HealthInvest Partners opened 1 new position and closed 5 in Q4 2021.
- HealthInvest Partners's portfolio value rose 6.3% quarter-over-quarter to $71M.
Based on HealthInvest Partners's 13F filing for Q4 2021, filed 18 Jan 2022.